APA (7th ed.) Citation

C, Z., BY, J., LX, Y., LS, P., JH, L., ZY, C., . . . WZ, Z. (2026). Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): Phase II trial and correlative genomic analysis in China. EClinicalMedicine, 96, 103994. https://doi.org/10.1016/j.eclinm.2026.103994

Chicago Style (17th ed.) Citation

C, Zhang, et al. "Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-mutant Non-small Cell Lung Cancer (NEOTIDE/CTONG2104): Phase II Trial and Correlative Genomic Analysis in China." EClinicalMedicine 96 (2026): 103994. https://doi.org/10.1016/j.eclinm.2026.103994.

MLA (9th ed.) Citation

C, Zhang, et al. "Neoadjuvant Sintilimab Plus Chemotherapy in EGFR-mutant Non-small Cell Lung Cancer (NEOTIDE/CTONG2104): Phase II Trial and Correlative Genomic Analysis in China." EClinicalMedicine, vol. 96, 2026, p. 103994, https://doi.org/10.1016/j.eclinm.2026.103994.